Insurtech's Best Quarter in Four Years Was Eight Cheques

Global insurtech funding reached $2.4B across 107 deals in Q2'26, the highest quarterly total since Q3'22, according to CB Insights ^[1][2]. The composition matters more than the headline: eight mega-rounds carried the quarter, and four property and casualty companies collected 58% of the dollars ^[3][4].

Those four are Corgi, ICEYE, Reserv, and Upstage, with a combined $1.4B ^[4]. That is an average of roughly $350M per company ^[12]. Strip them out and about $1.0B remains for everyone else ^[8]. If each of the four raised in a single round, the other 103 deals split something in the order of $9.7M apiece ^[9], against a headline average of about $22.4M per deal ^[10]. Put differently, under 4% of the quarter's deals absorbed more than half the quarter's capital ^[11].

CB Insights' own read is that investors are writing bigger cheques to fewer companies, a pattern consistent with the wider venture market ^[5]. Its brief is unsentimental about the other side of the ledger, describing a best-quarter-in-four-years total alongside deal counts that continue to collapse ^[6]. That combination is not a market reopening. A quarterly total assembled from eight financings can be dismantled by the absence of eight financings in the next quarter, and it carries almost no information about whether a $5M seed or a $20M Series A is available. That smaller tier is where most insurtech operators actually raise.

The P&C skew is worth sitting with. Four companies in one segment produced 58% of global insurtech funding ^[4]. Anyone benchmarking a round against "insurtech in Q2'26" is benchmarking against a distribution dominated by companies large enough to absorb nine-figure cheques, not against a comparable set. The brief names the four P&C recipients but does not identify the remaining mega-rounds or the segments they came from ^[13], so how much of the residual $1.0B ^[8] went to life, health, benefits, or distribution software is not visible from this summary; CB Insights points to its State of Insurtech Q2'26 report for the fuller breakdown ^[7].

For operators, the practical implications are narrow and specific. Aggregate funding totals are now a poor proxy for capital availability, because a single large round moves the number by a percentage point or two and a single quarter of mega-round drought erases the trendline. Deal count is the more honest indicator of whether new companies are getting funded at all, and by CB Insights' account it is still going the wrong way ^[6]. Concentration also means the segment's narrative gets written by a handful of large balance sheets, which shapes what later-stage investors expect to see from everyone else.

What to watch: whether Q3'26 deal counts stabilise or keep falling; whether the dollar share going to non-mega rounds recovers or continues to thin; and whether P&C repeats as the concentration point or the next quarter's mega-rounds land in a different segment.